Phase 2 N=16 Ketamine and Nitroprusside for Depression
Depression
Primary: Montgomery-Asberg Depression Rating Scale — 13.4; 14.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 A Rollover Protocol of Dacomitinib For Patients In Japan
NSCLC
Primary: Number of Participants Who Were Previously Treated With Dacomitinib on the Parent Study in Japan and Who Got Access to Dacomitinib in This Extension Study — 7 Participants
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
Phase 2 N=11 Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
Alopecia Universalis (AU) · Alopecia Totalis (AT)
Primary: Double Blind Period: ATI-50002 Levels in Scalp Biopsy (ng/g) - Pharmacodynamic (PD) Population at Day 2 and Day 29 — 166.0; 579.7; NA; 5710.0 ng/g
Phase 2 N=12 Valchlor in the Treatment of Lichen Planopilaris
Lichen Planopilaris
Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014
Phase 2 N=160 Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 2.96; 3.02 months — p=0.544
Phase 2 N=35 Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Rate of Complete Response/Complete Remission (CR), as Assessed by Investigator Using Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008…
Phase 2 N=60 Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Percentage of Participants With Freedom From Progression (FFP) for at Least 3 Cycles — 35.6 percentage of participants
Phase 2 N=12 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001
Phase 2 N=50 Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
Hemorrhagic Hereditary Telangiectasia (HHT)
Primary: Percentage of Patients Experiencing an Improvement in Their Nosebleeds — 10; 9 Participants — p=<0.05
Phase 2 N=54 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Myelofibrosis
Primary: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score — 0; 16.7; 6.7; 13.3…
Phase 2 N=85 AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
Advanced Renal Cell Carcinoma
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations (DCs) Due to Adverse Events (AEs) — 43; 42…
Phase 2 N=27 Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
X-linked Retinoschisis
Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants
Phase 2 N=80 Ramelteon in the Prevention of Post-operative Delirium
Delirium · Delirium, Dementia, Amnestic, Cognitive Disorders · Delayed Emergence From Anesthesia
Primary: Number of Participants With Delirium During Two Days Following Surgery — 3; 2 Participants
Phase 2 N=150 A Dose-finding Study of ASP4070
Rhinitis, Allergic, Seasonal
Primary: Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183 — 2.04; 1.91; 1.98 units on a…